Table 1.

Patient Characteristics

			Cohort
		All	Original	High-Dose	dMMR
		N (%)	N (%)	N (%)	N (%)
All		75 (100%)	50 (100%)	20 (100%)	5 (100%)
Age- median (min,max)	N=75	56 (35,72)	54 (35,72)	58.5 (40,68)	52 (45,64)
Gender
	Female	33 (44%)	22 (44%)	9 (45%)	2 (40%)
	Male	42 (56%)	28 (56%)	11 (55%)	3 (60%)
Race/Ethnicity
	White/Non-Hispanic	45 (60%)	30 (60%)	14 (70%)	1 (20%)
	Black/Non-Hispanic	17 (23%)	12 (24%)	3 (15%)	2 (40%)
	Asian-PI/Non-Hispanic	2 (3%)	2 (4%)	0 (0%)	0 (0%)
	Any/Hispanic	3 (4%)	2 (4%)	1 (5%)	0 (0%)
	Unknown	8 (11%)	4 (9%)	2 (10%)	2 (22%)
ECOG
	0	22 (29%)	15 (30%)	4 (20%)	3 (60%)
	1	51 (68%)	33 (66%)	16 (80%)	2 (40%)
	2	2 (3%)	2 (4%)	0 (0%)	0 (0%)
Number of Primary Therapies -median (min,max)	N=75	3 (2,7)	3 (2,7)	3 (2,5)	3 (2,5)
Therapies*
	Cetuximab/Panitumumab	37 (49%)	26 (52%)	9 (45%)	2 (40%)
	Other Therapy	13 (17%)	10 (20%)	3 (15%)	0 (0%)
MMR
	Stable	49 (65%)	29 (58%)	20 (100%)	0 (0%)
	dMMR	6 (8%)	1 (2%)	0 (0%)	5 (100%)
	Indeterminate	2 (3%)	2 (4%)	0 (0%)	0 (0%)
	Missing	18 (24%)	18 (36%)	0 (0%)	0 (0%)
PTEN
	LOSS	30 (40%)	23 (46%)	7 (35%)	0 (0%)
	NO LOSS	19 (25%)	16 (32%)	3 (15%)	0 (0%)
	Missing	26 (35%)	11 (22%)	10 (50%)	5 (100%)
MGMT
	NEG	26 (35%)	23 (46%)	3 (15%)	0 (0%)
	POS	22 (29%)	13 (26%)	9 (45%)	0 (0%)
	Missing	27 (36%)	14 (28%)	8 (40%)	5 (100%)
KRAS
	Mutant	38 (51%)	26 (52%)	11 (55%)	1 (20%)
	WT	29 (39%)	18 (36%)	8 (40%)	3 (60%)
	Missing	8 (11%)	6 (12%)	1 (5%)	1 (20%)

^*All patients received prior 5-fluorouracil, oxaliplatin, irinotecan, and bevacizumab. These are additional prior therapies